ImmuCell (NASDAQ:ICCC) released its earnings results on Thursday. The biotechnology company reported ($0.04) earnings per share for the quarter, Bloomberg Earnings reports. ImmuCell had a return on equity of 0.28% and a net margin of 0.60%. The business had revenue of $3.13 million during the quarter.
ImmuCell (NASDAQ:ICCC) opened at $7.38 on Friday. The company has a market capitalization of $39.02, a price-to-earnings ratio of 738.00 and a beta of 1.03. ImmuCell has a 52 week low of $5.00 and a 52 week high of $9.25. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.99 and a current ratio of 1.75.
Separately, ValuEngine upgraded ImmuCell from a “sell” rating to a “hold” rating in a research note on Wednesday, October 18th.
ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis.
Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with MarketBeat.com's FREE daily email newsletter.